Cochlear Ltd higher Friday, outperforms the Health Care sector
Here is the latest company close update for Cochlear Ltd, COH.
Cochlear
How automation will let people be heard: Cochlear CEO
Dig Howitt says automation already plays an important role in his products, and he sees it as an enabler in achieving the mission to help people hear and be heard.
Follow Europe or Trump’s US: Cochlear boss sounds warning
Australia can either go down a US-style push to deregulate or continue its current European-style path of increasing regulations on business, says Cochlear CEO Dig Howitt.
When keeping an ear open and cashing in too early hurts
There is an investment mistake more painful and more costly than a 100 per cent loss and here’s what you can do to avoid it.
ASX 200 ends flat after intraday rise; WiseTech, HMC among top gainers; Metcash falls
ASX 200 rise fades for third day running. Qantas ‘might have not survived’ without Alan Joyce and Richard Goyder: chair. WiseTech investors back founder’s reincarnation as consultant. Metcash profit warning. ResMed lifts on strong quarter earnings.
Miners drag on ASX 200; Woodside, Mesoblast up
US President Joe Biden triggers oil price jump. Mesoblast top gainer. Sinopec wants price review on APLNG deal. Platinum grants Regal access for higher offer. Ratings upgrade for Cochlear. Optimism underpinning latest Bendigo Bank, UBS forecasts.
Increase R&D tax incentive cap, says Cochlear boss
Cochlear chief executive Dig Howitt says Australia needs to increase the research and development tax incentive threshold and dust off a Morrison government-era plan.
Cochlear talks up huge pipeline as shares slump on outlook miss
Digital savvy seniors and an expanding body of research on the benefits of hearing to cognition underpin Cochlear’s huge long term growth trajectory, chief executive Dig Howitt says.
ASX trims gains as Cochlear, Origin falls weigh; jobs data dims rates hopes
AUD rises on ‘quite tight’ jobs market. Cochlear, Origin sink on profit miss . Telstra rises despite profit fall. Treasury Wine lifts on China boost. Goodman dips on mixed results. Nufarm tumbles on earnings downgrade.
ASX 200 lifts as MinRes gains; Bellevue tanks
Investors welcome MinRes cash gains, price wins. Bellevue Gold downgraded on discounted equity raise. Inflation uptick may force RBA hike. Key exit triggers Cochlear executive rehaul.
Mission-oriented ‘moonshots’ the way to go
Universities are uniquely positioned to lead very specific and ambitious ‘moonshot’ research programs aimed at solving major global problems.
Business in tizz over meeting with Beijing minister
Executives from Rio Tinto and Cochlear are expected to join the private event with China’s visiting foreign minister, as even business figures criticise Paul Keating’s “stupid” meeting with Wang Yi.
ASX 200 ends at record high
ASX 200 sets all-time high at close. Life360 soars 38 per cent on earnings beat. ASIC wants crime-linked Prospero wound up. China manufacturing activity better than expected but still weak.
Cochlear to pay record dividend but is best yet to come?
Cochlear has delivered a bumper first half profit, but at least one analyst says the company could be doing even better than the numbers suggest.
ASX ends flat; Lendlease leads property falls
Economy to remain resilient: Westpac. Bendigo Bank sees competition issues in ANZ’s Suncorp bid. Boral gains, Seven Group dips on takeover play. APM, A2 Milk soar.
ASX ends little changed; Boral jumps
RBA boss says lower inflation data key to unlocking rate cuts. Callide Power Trading faces court action. PwC’s Labor donation questioned. Stokes-backed Boral ups guidance.
Leukaemia trial lifts hopes, share price
Chimeric Therapeutics surged 12 per cent after announcing it had dosed the first leukaemia patient with its cell therapy as part of a Phase 1B clinical trial.
ASX gains; AGL soars, REA drops
Iron ore miners trim gains as China’s CPI falls at fastest pace since 2009. Investors back News Corp, AGL earnings updates. Cochlear up on profit upgrade. REA Group, Transurban and Alliance Aviation drop.
Bullock: not ruling out rate hike or cuts
Bullock says RBA not ruling anything in or out regarding rate cuts and hikes, after holds cash rate. Bullock says November hike ‘not a mistake’, and RBA doesn’t want to cut too early. ASX 200 ends lower.
Cochlear sticks to profit guidance
CEO Dig Howitt says there is still significant, unmet and addressable clinical need for cochlear and acoustic implants, underpinning the company’s growth.
Original URL: https://www.theaustralian.com.au/topics/cochlear